Previous research has shown that TMB emerged as a negative correlation with clinical outcomes in patients with advanced NSCLC harboring EGFR mutations who were treated with first‐ or second‐generation EGFR‐TKI [29, 36, 37, 38]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.